002019 亿帆医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,632,09035.39%4,068,1073,836,6414,409,0365,400,381
减:营业总成本2,363,16231.50%4,041,9343,650,2594,183,7474,436,702
    其中:营业成本1,374,81042.75%2,121,9331,970,7012,580,6512,890,466
               财务费用32,25882.61%58,82822,23772,22467,324
               资产减值损失(10,824)-30.61%(887,364)(111,543)(48,272)(10,370)
公允价值变动收益----10502(14)(14)
投资收益(1,289)-82.78%(15,069)(18,135)(4,476)6,947
    其中:对联营企业和合营企业的投资收益(15,244)92.18%(19,233)(18,135)(18,341)110
营业利润291,472184.13%(882,712)143,808212,1981,084,556
利润总额293,651183.17%(869,031)156,737210,7891,080,713
减:所得税费用81,205326.74%16,61929,651(31,425)149,319
净利润212,446150.90%(885,649)127,085242,214931,394
减:非控股权益(40,781)70.00%(334,576)(64,133)(36,185)(36,997)
股东净利润253,227133.04%(551,073)191,218278,399968,391

市场价值指针
每股收益 (元) *0.210133.33%-0.4500.1600.2300.800
每股派息 (元) *0.100--------0.050
每股净资产 (元) *6.944-5.22%6.7507.1876.9166.836
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容